Full Press Release Details
Unassociated Document.
ASMB
Unassociated Document
Key Takeaway: Unassociated Document
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+90%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Cash runway
~62 mo
Minimal dilution risk
Lead asset
ABI-H0731
Phase 2 · Chronic Hepatitis B